Current Evidence on Therapeutic Approaches to BCBM: HER2-Negative Disease

Slides from Sara Tolaney, MD, MPH, on adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Sara Tolaney, MD, MPH Released: June 16, 2021

Slides from Joyce O’Shaughnessy, MD, on measures of treatment benefit for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Released: June 15, 2021

Slides from Sara Hurvitz, MD, FACP, on neoadjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: June 15, 2021

MONALEESA-3 updated survival analysis with ribociclib + fulvestrant in advanced breast cancer, from ASCO 2021 as reported by Clinical Care Options (CCO)